abbv-428
mAbexperimentalMulti-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02955251)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor necrosis factor receptor superfamily member 5Immunity, passive
CD40 immunity, passive
- MesothelinImmunity, passive
MSLN immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- abbv-428
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02955251 | Phase 1 | Nov 1, 2016 | AbbVie |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 1 | 1 | 1 | 2016 |
1 organizations
Page 1 / 1